U.S. markets close in 6 hours 4 minutes
  • S&P 500

    3,930.92
    -10.34 (-0.26%)
     
  • Dow 30

    33,536.95
    -59.39 (-0.18%)
     
  • Nasdaq

    10,945.68
    -69.21 (-0.63%)
     
  • Russell 2000

    1,817.18
    +4.60 (+0.25%)
     
  • Crude Oil

    74.94
    +0.69 (+0.93%)
     
  • Gold

    1,799.40
    +17.00 (+0.95%)
     
  • Silver

    22.94
    +0.61 (+2.73%)
     
  • EUR/USD

    1.0521
    +0.0052 (+0.49%)
     
  • 10-Yr Bond

    3.4620
    -0.0510 (-1.45%)
     
  • GBP/USD

    1.2211
    +0.0078 (+0.64%)
     
  • USD/JPY

    136.6620
    -0.2980 (-0.22%)
     
  • BTC-USD

    16,836.28
    -169.91 (-1.00%)
     
  • CMC Crypto 200

    395.48
    -6.55 (-1.63%)
     
  • FTSE 100

    7,533.41
    +12.02 (+0.16%)
     
  • Nikkei 225

    27,686.40
    -199.47 (-0.72%)
     

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET followed by a live Q&A session with registered investors and other conference attendees. In addition, Mr. Eiswirth will be available for virtual one-on-one meetings the same day.

Registration link: https://us02web.zoom.us/webinar/register/WN_AnmlPmPwSHGD5rRTJtxp6w

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com

For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com